ERBB2 and breast cancer: Lapatinib is the first TKI approved for the treatment of HER2-postive advanced BC (58), which effectively inhibits phosphorylation of the epidermal growth factor receptor, blocks the downstream transmission of mitogenic signaling pathways, arrests tumor cell proliferation and differentiation, and promotes cell apoptosis (59).